News

Portfolio Companies
in the News

Gynesonic Names Industry veteran skip baldino president and ceo, announces $25M financing to expand worldwide commercialization

April 11, 2023

Thryv Therapeutics Inc. Announces Completion of Initial Phase 1 Clinical Study and Beginning of Proof of Efficacy Study in Long QT Syndrome

March 14, 2023

Miach Orthopaedics Secures $40 Million Financing

January 25, 2023

Contego Medical Completes Enrollment of the PERFORMANCE II Carotid Stent Trial

November 14, 2022

Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints

June 6, 2022

ShiraTronics, Inc. Welcomes New CEO – Robert Binney

May 12, 2022

Impulse Dynamics Completes $101M Financing Round

May 12, 2022

Seminal Research for Miach Orthopaedics’ BEAR® Implant Wins OREF Award

February 7, 2022

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

November 3, 2021

category

medtech

status

Current

headquarters

Plymouth, Minnesota

website

HistoSonics

HistoSonics has developed a system to destroy tumors completely non-invasively. Treatment is achieved using histotripsy, a novel form of energy that is safe, extremely precise, and able to be personalized for each patient. The initial indication is for treatment of liver tumors and the system is being studied in several other types of tumors.